What is the appropriate ICD‑10‑CM coding for Wegovy (semaglutide) in a patient with a body mass index of 46.36, essential hypertension, a personal history of deep vein thromboses, and prediabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10-CM Coding for Wegovy in a Patient with BMI 46.36, Hypertension, History of DVTs, and Prediabetes

The appropriate ICD-10 codes for this patient are: E66.01 (Morbid obesity due to excess calories), I10 (Essential hypertension), Z86.718 (Personal history of other venous thrombosis and embolism), and R73.03 (Prediabetes). This coding captures all relevant diagnoses that support medical necessity for Wegovy (semaglutide 2.4 mg) prescription.

Primary Diagnosis Code

E66.01 (Morbid obesity due to excess calories) is the principal diagnosis code, as this patient's BMI of 46.36 kg/m² falls into Class III obesity (morbid obesity) 1. This code is essential for insurance coverage of Wegovy, which is FDA-approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity 1.

Weight-Related Comorbidity Codes

Hypertension

I10 (Essential [primary] hypertension) documents the patient's hypertension, which is a qualifying weight-related comorbidity for Wegovy 1. This is particularly relevant as:

  • Semaglutide 2.4 mg significantly reduces systolic blood pressure (mean reduction of 5.7 mmHg in STEP 8 trial) 2
  • The 2024 ESC guidelines specifically recommend GLP-1 receptor agonists for weight reduction in patients with hypertension and obesity 3
  • Orlistat, liraglutide, phentermine/topiramate, and semaglutide are preferred weight-loss medications in patients with existing hypertension 4

History of Deep Vein Thrombosis

Z86.718 (Personal history of other venous thrombosis and embolism) captures the DVT history. This is clinically significant because:

  • The patient's history of DVTs represents a cardiovascular risk factor that may benefit from weight reduction 3
  • While there are isolated case reports of DVT with GLP-1 RAs 5, a 2026 meta-analysis found that GLP-1 RAs were associated with lower VTE risk compared to DPP-4 inhibitors (HR 0.78; 95% CI 0.73-0.83) 6
  • Weight loss itself reduces thrombotic risk through multiple mechanisms including improved endothelial function and reduced inflammation 7

Prediabetes

R73.03 (Prediabetes) documents the prediabetic state, which is both a qualifying comorbidity and a strong indication for semaglutide:

  • Semaglutide 2.4 mg is a first-tier medication for preventing progression to overt diabetes due to substantial weight loss and direct glycemic effects 8
  • In the STEP trials, semaglutide increased regression to normoglycemia by up to 84% and significantly reduced progression to diabetes 9
  • The 2024 ESC guidelines recommend BP-lowering drug treatment for people with prediabetes or obesity when office BP is ≥140/90 mmHg 10

Alternative or Additional Codes to Consider

E66.9 (Obesity, unspecified) can be used if more specific obesity coding is not required, though E66.01 is more precise for this patient's BMI.

Z68.43 (Body mass index [BMI] 45.0-49.9, adult) may be added as a supplementary code to document the specific BMI value, though this is optional as the obesity diagnosis code already captures the severity.

Clinical Justification for Medical Necessity

This coding combination strongly supports medical necessity for Wegovy because:

  1. Multiple qualifying comorbidities: The patient has at least three weight-related comorbidities (hypertension, prediabetes, history of DVT), exceeding the FDA requirement of one comorbidity for BMI ≥27 kg/m² 1

  2. Cardiovascular risk reduction: Semaglutide 2.4 mg demonstrated a 20% reduction in cardiovascular death in the SELECT trial, which included patients with similar risk profiles 7, 3

  3. Cardiometabolic benefits: Real-world data shows semaglutide 2.4 mg users had significantly lower risks for incident type 2 diabetes (HR 0.45-0.75), hypertension, and cardiovascular disease 11

  4. Guideline support: The 2025 AHA/ACC guidelines and 2024 ESC guidelines both recommend GLP-1 receptor agonists for weight management in patients with obesity and cardiovascular risk factors 2, 3

Important Coding Considerations

  • Do not use diabetes codes (E11.x series) unless the patient has been diagnosed with type 2 diabetes; prediabetes requires the R73.03 code
  • Document failed lifestyle interventions in the medical record, as Wegovy is indicated for patients who have had inadequate response to lifestyle modifications 12, 1
  • Include documentation of BMI calculation in the medical record to support the E66.01 code
  • Consider adding Z79.84 (Long-term use of oral hypoglycemic drugs) if the patient is on metformin for prediabetes, though this is not required for Wegovy coding

References

Guideline

american association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2016

Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

Can Wegovy (semaglutide) be taken together with Eliquis (apixaban) without dose adjustment?
What were the efficacy outcomes and dosing protocol of the 68‑week semaglutide 2.4 mg (subcutaneous) weight‑loss trial in adults with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities)?
What special considerations are there when switching from Wegovy (semaglutide) to Zepbound (tirzepatide)?
Is tirzepatide (Mounjaro) appropriate for a patient with prediabetes (HbA1c 6.6 %), borderline cholesterol and hyperuricemia, or should metformin and lifestyle modifications be initiated instead?
For a 33-year-old patient who has been on oral semaglutide (Rybelsus) 9 mg daily for at least one year, can the injectable semaglutide (Ozempic) be initiated at a dose of 0.5 mg weekly?
What is the appropriate endocrine management for a young patient with traumatic brain injury and central hypothyroidism who now presents with hypernatremia and azotemia?
What percentage of patients have a false‑positive rheumatoid factor overall and in those older than 65 years?
What are serum immunoglobulin A (IgA) levels and how can they be increased when deficient?
How do I write a prescription for ketoconazole (Nizoral) 2% shampoo?
Can you provide a SOAP note with appropriate CPT and ICD‑10 codes for a 14‑year‑old female follow‑up visit for acute paronychia of the right index finger with mild cellulitis, after completing oral antibiotics and planning incision and drainage and topical mupirocin?
What is the significance of anterior pituitary lobe bowing upward against the diaphragma sellae on imaging, and what evaluation and management steps are recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.